These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 26386787)

  • 41. Effect of Technique on Outcomes Following Bioresorbable Vascular Scaffold Implantation: Analysis From the ABSORB Trials.
    Stone GW; Abizaid A; Onuma Y; Seth A; Gao R; Ormiston J; Kimura T; Chevalier B; Ben-Yehuda O; Dressler O; McAndrew T; Ellis SG; Kereiakes DJ; Serruys PW
    J Am Coll Cardiol; 2017 Dec; 70(23):2863-2874. PubMed ID: 29100704
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Arterial healing following primary PCI using the Absorb everolimus-eluting bioresorbable vascular scaffold (Absorb BVS) versus the durable polymer everolimus-eluting metallic stent (XIENCE) in patients with acute ST-elevation myocardial infarction: rationale and design of the randomised TROFI II study.
    Räber L; Onuma Y; Brugaletta S; Garcia-Garcia HM; Backx B; Iñiguez A; Okkels Jensen L; Cequier-Fillat À; Pilgrim T; Christiansen EH; Hofma SH; Suttorp M; Serruys PW; Sabaté M; Windecker S
    EuroIntervention; 2016 Jul; 12(4):482-9. PubMed ID: 26342471
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of everolimus- and paclitaxel-eluting stents in patients with acute and stable coronary syndromes: pooled results from the SPIRIT (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (A Trial of Everolimus-Eluting Stents and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice) Trials.
    Planer D; Smits PC; Kereiakes DJ; Kedhi E; Fahy M; Xu K; Serruys PW; Stone GW
    JACC Cardiovasc Interv; 2011 Oct; 4(10):1104-15. PubMed ID: 22017936
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term clinical outcomes of everolimus-eluting bioresorbable scaffolds versus everolimus-eluting stents: final five-year results of the AIDA randomised clinical trial.
    Kerkmeijer LSM; Renkens MPL; Tijssen RYG; Hofma SH; van der Schaaf RJ; Arkenbout EK; Weevers APJD; Garcia-Garcia HM; Kraak R; Piek JJ; Tijssen JGP; Henriques JPS; de Winter RJ; Wykrzykowska JJ
    EuroIntervention; 2022 Mar; 17(16):1340-1347. PubMed ID: 34483094
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The relationship of pre-procedural Dmax based sizing to lesion level outcomes in Absorb BVS and Xience EES treated patients in the AIDA trial.
    Tijssen RYG; Kerkmeijer LSM; Katagiri Y; Kraak RP; Takahashi K; Kogame N; Chichareon P; Modolo R; Asano T; Nassif M; Kalkman DN; Sotomi Y; Collet C; Hofma SH; van der Schaaf RJ; Arkenbout EK; Weevers APJD; Beijk MAM; Piek JJ; Tijssen JGP; Henriques JP; de Winter RJ; Onuma Y; Serruys PW; Wykrzykowska JJ
    Int J Cardiovasc Imaging; 2019 Jul; 35(7):1189-1198. PubMed ID: 30911857
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial.
    von Birgelen C; Basalus MW; Tandjung K; van Houwelingen KG; Stoel MG; Louwerenburg JH; Linssen GC; Saïd SA; Kleijne MA; Sen H; Löwik MM; van der Palen J; Verhorst PM; de Man FH
    J Am Coll Cardiol; 2012 Apr; 59(15):1350-61. PubMed ID: 22341737
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Three-year clinical outcomes of the absorb bioresorbable vascular scaffold compared to Xience everolimus-eluting stent in routine PCI in patients with diabetes mellitus-AIDA sub-study.
    Kerkmeijer LSM; Tijssen RYG; Hofma SH; van der Schaaf RJ; Arkenbout EK; Weevers APJD; Kraak RP; Onuma Y; Serruys PW; Piek JJ; Tijssen JGP; Henriques JPS; de Winter RJ; Wykrzykowska JJ
    Catheter Cardiovasc Interv; 2021 Oct; 98(4):713-720. PubMed ID: 33118696
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of everolimus-eluting bioresorbable vascular scaffolds and metallic stents: three-year clinical outcomes from the ABSORB China randomised trial.
    Xu B; Yang Y; Han Y; Huo Y; Wang L; Qi X; Li J; Chen Y; Kuo HC; Ying SW; Cheong WF; Zhang Y; Su X; Popma JJ; Gao R; Stone GW
    EuroIntervention; 2018 Aug; 14(5):e554-e561. PubMed ID: 30082268
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of the short- and long-term safety and therapy outcomes of the everolimus-eluting bioresorbable vascular scaffold system in patients with coronary artery stenosis: Rationale and design of the German-Austrian ABSORB RegIstRy (GABI-R).
    Nef H; Wiebe J; Achenbach S; Münzel T; Naber C; Richardt G; Mehilli J; Wöhrle J; Neumann T; Biermann J; Zahn R; Kastner J; Schmermund A; Pfannebecker T; Schneider S; Limbourg T; Hamm CW
    Cardiovasc Revasc Med; 2016; 17(1):34-7. PubMed ID: 26431767
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bioresorbable vascular scaffolds for the treatment of coronary artery disease: Clinical outcomes from randomized controlled trials.
    Rizik DG; Hermiller JB; Kereiakes DJ
    Catheter Cardiovasc Interv; 2016 Nov; 88(S1):21-30. PubMed ID: 27797464
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Overview of the 2016 U.S. Food and Drug Administration Circulatory System Devices Advisory Panel Meeting on the Absorb Bioresorbable Vascular Scaffold System.
    Steinvil A; Rogers T; Torguson R; Waksman R
    JACC Cardiovasc Interv; 2016 Sep; 9(17):1757-64. PubMed ID: 27609249
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Primary endpoint results of the EVOLVE trial: a randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent.
    Meredith IT; Verheye S; Dubois CL; Dens J; Fajadet J; Carrié D; Walsh S; Oldroyd KG; Varenne O; El-Jack S; Moreno R; Joshi AA; Allocco DJ; Dawkins KD
    J Am Coll Cardiol; 2012 Apr; 59(15):1362-70. PubMed ID: 22341736
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The SPIRIT V study: a clinical evaluation of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions.
    Grube E; Chevalier B; Smits P; Džavík V; Patel TM; Mullasari AS; Wöhrle J; Stuteville M; Dorange C; Kaul U;
    JACC Cardiovasc Interv; 2011 Feb; 4(2):168-75. PubMed ID: 21349455
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Rationale of a novel study design for the BIOFLOW V study, a prospective, randomized multicenter study to assess the safety and efficacy of the Orsiro sirolimus-eluting coronary stent system using a Bayesian approach.
    Doros G; Massaro JM; Kandzari DE; Waksman R; Koolen JJ; Cutlip DE; Mauri L
    Am Heart J; 2017 Nov; 193():35-45. PubMed ID: 29129253
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Time-Varying Outcomes With the Absorb Bioresorbable Vascular Scaffold During 5-Year Follow-up: A Systematic Meta-analysis and Individual Patient Data Pooled Study.
    Stone GW; Kimura T; Gao R; Kereiakes DJ; Ellis SG; Onuma Y; Chevalier B; Simonton C; Dressler O; Crowley A; Ali ZA; Serruys PW
    JAMA Cardiol; 2019 Dec; 4(12):1261-1269. PubMed ID: 31561250
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bioresorbable Scaffold for Treatment of Coronary Artery Lesions: Intravascular Ultrasound Results From the ABSORB Japan Trial.
    Okada K; Honda Y; Kitahara H; Otagiri K; Tanaka S; Hollak MB; Yock PG; Popma JJ; Kusano H; Cheong WF; Sudhir K; Fitzgerald PJ; Kimura T;
    JACC Cardiovasc Interv; 2018 Apr; 11(7):648-661. PubMed ID: 29622143
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents.
    Sorrentino S; Giustino G; Mehran R; Kini AS; Sharma SK; Faggioni M; Farhan S; Vogel B; Indolfi C; Dangas GD
    J Am Coll Cardiol; 2017 Jun; 69(25):3055-3066. PubMed ID: 28412389
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials.
    Bangalore S; Kumar S; Fusaro M; Amoroso N; Attubato MJ; Feit F; Bhatt DL; Slater J
    Circulation; 2012 Jun; 125(23):2873-91. PubMed ID: 22586281
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Biodegradable polymer versus permanent polymer drug-eluting stents and everolimus- versus sirolimus-eluting stents in patients with coronary artery disease: 3-year outcomes from a randomized clinical trial.
    Byrne RA; Kastrati A; Massberg S; Wieczorek A; Laugwitz KL; Hadamitzky M; Schulz S; Pache J; Fusaro M; Hausleiter J; Schömig A; Mehilli J;
    J Am Coll Cardiol; 2011 Sep; 58(13):1325-31. PubMed ID: 21920260
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Arterial Remodeling After Bioresorbable Scaffolds and Metallic Stents.
    Serruys PW; Katagiri Y; Sotomi Y; Zeng Y; Chevalier B; van der Schaaf RJ; Baumbach A; Smits P; van Mieghem NM; Bartorelli A; Barragan P; Gershlick A; Kornowski R; Macaya C; Ormiston J; Hill J; Lang IM; Egred M; Fajadet J; Lesiak M; Windecker S; Byrne RA; Räber L; van Geuns RJ; Mintz GS; Onuma Y
    J Am Coll Cardiol; 2017 Jul; 70(1):60-74. PubMed ID: 28662808
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.